Prof Garcia-Manero speaks with ecancertv at ASH 2016 about results from a phase II trial of pracinostat and azacitidine for elderly patients with acute myeloid leukaemia.

He describes how, while negative results for the combination in treating MDS might be attributed to inappropriate dose levels, pracinostat is proving highly efficacious in treating AML with a promising outlook on further combinations in randomised trials.

Prof Garcia-Manero also spoke with ecancer about the value of including patients who fail eligibility criteria in clinical trials.

ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.